Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.
Also called NCT01879319
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 164 participants
- Sponsor
- Registry
-
NCT01879319
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- Not reported
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT01879319. Randomized; no masking; primary purpose treatment. Start 2013-07-11 (actual); primary completion 2013-11-15 (actual). Results posted on 2015-12-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
- Condition
- Primary Hypercholesterolemia
- Condition
- Mixed Dyslipidemia
- Intervention (Biological)
- Evolocumab AMD
- Intervention (Biological)
- Evolocumab AI/pen
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01879319- Content hash
59beeaae2e6176ef4a666d2d4da9b1c45358d90d98cc7f94b24e6f86e6a07745